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Abstract
Background: Keratinocyte growth factor (KGF; palifermin) is a growth factor with a high degree of specificity for epithelial
cells. KGF is an important effector of epithelial growth and tissue homeostasis in various organs including the
pancreas. Here we investigated the intracellular signaling pathways involved in the mediation of pancreatic ductal cell
proliferation and differentiation induced by exogenous KGF during beta-cell regeneration in diabetic rat.
Methodology and Results: In vitro and in vivo duct cell proliferation was measured by BrdU incorporation assay. The
implication of MAPK-ERK1/2 in the mediation of KGF-induced cell proliferation was determined by inactivation of this
pathway, using the pharmacological inhibitor or antisense morpholino-oligonucleotides against MEK1. In vivo KGF-induced
duct cell differentiation was assessed by the immunolocalization of PDX1 and Glut2 in ductal cells and the implication of
PI3K/AKT in this process was investigated. We showed that KGF exerted a potent mitogenic effect on ductal cells. Both in
vitro and in vivo, its effect on cell proliferation was mediated through the activation of ERK1/2 as evidenced by the abolition
of duct cell proliferation in the context of MEK/ERK inactivation. In vivo, KGF treatment triggered ductal cell differentiation
as revealed by the expression of PDX1 and Glut2 in a subpopulation of ductal cells via a PI3K-dependent mechanism.
Conclusion: Here we show that KGF promotes beta-cell regeneration by stimulating duct cell proliferation in vivo.
Moreover, we demonstrated for the first time that KGF directly induces the expression of PDX1 in some ductal cells thus
inducing beta-cell neogenesis. We further explored the molecular mechanisms involved in these processes and showed that
the effects of KGF on duct cell proliferation are mediated by the MEK-ERK1/2 pathway, while the KGF-induced cell
differentiation is mediated by the PI3K/AKT pathway. These findings might have important implications for the in vivo
induction of duct-to-beta cell neogenesis in patients with beta-cell deficiency.
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Introduction
The shortage of isletfor transplantation isa majorobstacle forthe
wide application of beta cell replacement therapy in type 1 diabetic
patients. To make such a therapy readily available, new sources of
insulin-producing cells must be identified. Pancreatic duct cells
represent such an alternative source for generation of new beta cells
in vitro [1]. Duct compartment has also implications in type 2
diabetes(T2D),sinceT2Disassociatedwithbeta cellloss,andthein
situ induction of beta cell neogenesis from ductal progenitor cells
may help to restore the beta cell mass in the pancreas of type 2
diabetic patients. Therefore, characterization of stimuli with
potential to induce the expansion of duct cells and/or to drive
their differentiation into beta cells is of great importance. A variety
of growth factors have been described to induce growth and
differentiation of ductal cells. Fibroblast growth factors (FGFs)
comprise a growing group of structurally related polypeptide
mitogens with more than 20 members, most of which stimulate
proliferation of a variety of cell types [2,3]. Keratinocyte growth
factor, also called FGF7, is a member of the FGF family. KGF is a
paracrine-acting mitogen produced by cells of mesenchymal origin.
It acts exclusively through a subset of FGF receptor isoforms
(FGFR2IIIb) expressed predominantly by epithelial cells and
therefore is a specific mitogen for these cells [4]. Preclinical data
from several animal models have demonstrated that recombinant
human KGF could enhance the regenerative capacity of epithelial
tissues and protect them from a variety of toxic exposures [3]. We
and others have previously reported that KGF induces ductal cell
proliferation in the pancreas [5–8] and promotes beta cell
regeneration in neonatal streptozotocin diabetic rats [6]. However
the molecular mechanisms underlying the stimulation of beta cell
regeneration through the induction of ductal cell proliferation and
beta cell neogenesis by KGF are not known.
The present study was undertaken to investigate the intracel-
lular signaling pathways which mediate the growth promoting
effects of KGF (palifermin) in pancreatic ducts and to dissect the
key steps of duct-to-beta cell differentiation induced by KGF in a
model of neonatal diabetes in rat.
In our study, we have established that KGF acts on ductal cells
by the the activation of distinct signaling pathways to promote beta
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cells via the activation of the MEK-ERK1/2 pathway and it
triggers duct-to-beta cell differentiation directly by the induction of
PDX1 expression in the neonatal ducts via the activation of PI3K/
AKT pathway. The duality of the effects of KGF in a different
subsets of a unique cell type is an original finding and could have
important implication in the potential use of this factor as
differentiation promoting agent for regenerative therapies of
diabetes.
Materials and Methods
Reagents
The following chemicals and reagents were used in this
study. DMEM was purchased from Promochem (Molsheim,
France), penicillin–streptomycin, and trypsin–EDTA solutions from
Invitrogen (Cergy Pontoise, France). Fetal bovine serum (FBS) was
purchased from Abcys (Paris, France). Keratinocyte growth factor,
palifermin (KGF) was generously provided by AMGEN (Thousand
Oaks, CA, USA). The pharmacological MEK1 inhibitor, PD98059
and total-ERK1/2 antibody were purchased from Promega
(Charbonnie `res, France). The phospho-ERK1/2 (Thr202/
Tyr204) and MEK1 antibodies were purchased from Ozyme (St
Quentinen Yvelines,France), cyclinD1 antibody was fromMicrom
(Francheville, France), cyclin D2 antibody and the protein assay
reagents werepurchasedfrom Interchim(Montluc ¸on, France), actin
antibody and wortmannin from Sigma (L’Isle-d’Abeau Chesnes,
France), PDX1 antibody from Millipore (St Quentin en Yvelines,
France), insulin antibody from MP Biomedicals (Aurora, Ohio,
USA), CK 20 antibody from Abcam (Paris, France) and Glut 2
antibody from AbD Serotec (Du ¨sseldorf, Germany). Antisense
morpholino-oligonucleotides to knock down endogenous MEK1
(MEK1-AS)expression were designed and produced by Gene Tools
LLC (Philomath, Oregon, USA).
Animals
Wistar rats were fed ad libitum with pelleted chow (diet 113,
SAVE, Villemoisson-sur-Orge, France). Females were caged with
males for one night and pregnancy was detected by abdominal
palpationafter14days.Naturalbirthoccurred22daysaftermating.
All animal experiments were conducted with the approval of
French Center for Scientific Research.
Eight experimental groups were studied
STZ/saline group. At the day of birth, rats of this group
received an injection of 100 mg/g body weight of streptozotocin
(STZ) (Sigma) freshly dissolved in citrate buffer (0.05 M, pH 4.5).
From day 2 to day 6, rats received an i.p. injection of saline solution.
Rats of this group were sacrificed at day 2, 4 or 7 after birth.
STZ/KGF group. At the day of birth, rats of this group
received a single daily i.p. injection of 100 mg/g body weight of
STZ freshly dissolved in citrate buffer (0.05 M, pH 4.5). From day
2 to day 6, rats received an s.c. injection of KGF (palifermin)
provided by AMGEN (Thousand Oaks, CA, USA) at the dose of
3 mg/kg body weight. For the evaluation of ERK1/2 activation
by KGF, 2-day-old pups received an i.p. injection of KGF
20 minutes before sacrifice.
STZ/MEK1-AS group. As for the above groups, Wistar
newborns received a single daily i.p injection of STZ. Eight hours
after STZ administration rats received a subcutaneous injection of
antisense morpholino-oligonucleotides targeted to the MEK1
mRNA translation site (MEK1-AS, 1 nmole/g). On day 2, 8 h
before sacrifice, rats underwent another s.c. injection of MEK1-AS.
STZ/Std group. Eight hours after STZ administration, rats
of STZ group received a subcutaneous injection of non specific
standard morpholino-oligonucleotides (Std). On day 2, rats
underwent another s.c. injection of Std 8 hours before sacrifice.
STZ/MEK1-AS/KGF group. In this group, 2-day-old STZ/
MEK1-AS treated animals received an injection of KGF (3 mg/kg
body weight) 8 hours before sacrifice.
STZ/Std/KGF group. In this group, STZ/Std treated
animals received an injection of KGF (3 mg/kg body weight;
i.p) 8 hours before sacrifice.
STZ/Wortmannin group. Rats of this group were given a
subcutaneous injection of wortmannin (0.75 mg/kg body weight),
on day 2, 24 hours after the administration of STZ.
STZ/Wortmannin/KGF group. In this group, rats were
pre-treated with wortmannin for one hour on day 2 and then
received an s.c injection of KGF. They were sacrificed 8 hours
after KGF administration.
In each group, the pups were left with the dams and kept in an
environment of constant temperature, humidity, and day–night
cycle. The number of animals per litter was kept at eight. For each
experimental group the pups belonged to at least three different
litters. All the neonates were tested for blood glucose concentration
(Glucotrend, Roche) 24 h after STZ administration. Animals were
included in the study only if their glycemia was higher than
9.35 mmol/l.
Animals were killed on day 2, 4 or 7 after birth. One hour
before the sacrifice, animals were given an injection of 59-bromo-
29-deoxyuridine (BrdU) (Sigma) at the dose of 50 mg/kg, i.p.
Pancreases were removed and half of the tails and heads were
used for immunohistochemistry and the other halves were used for
western blot analysis.
Immunohistochemistry
Pancreases were fixed in aqueous Bouin’s solution for 24 h and
embedded in Paraplast. Each piece of pancreatic tissue was serially
sectioned (5 mm) throughout its length. Sections at a fixed interval
throughout the block (every 35
th section) were immunostained for
BrdU using the cell proliferation kit (GE Healthcare, Orsay,
France) as described previously [9]. To identify ductal cells,
pancreatic sections were stained for cytokeratin 20 (CK20), a
specific marker of ductal cells in rat [10,11].
To estimate the ductal cell replication rate, ductal cells were
counted in CK20/BrdU double- stained pancreatic sections. After
BrdU staining, sections were stained for CK20 using an alkaline
phosphatase-conjugated antibody as secondary antibody. Results
were expressed as the percentage of BrdU-positive ductal cells. At
least 800 ductal cells were counted per pancreas, and four different
sections were analyzed for each pancreas.
In order to assess ductal cell differentiation, we sought to
identify ductal cells with intermediate phenotype. These consisted
of cells that expressed specific beta cell markers that are not
normally expressed in ductal cells. As such markers, we
investigated the expression of PDX1 and the beta cell specific
glucose transporter, Glut 2. Since both CK20 and PDX1
antibodies were raised in rabbit, double staining using both
antibodies on the same section could not be carried out.
Therefore, in order to localize the PDX1 expressing ductal cells
in the pancreatic sections of 2-day-old rats , double staining for
insulin and PDX1 were performed in sections adjacent to those
that were stained for CK20. To estimate the number of PDX1-
positive cells, ductal cells that were positive for PDX1, but negative
for insulin were counted and the results were expressed as the
percentage of PDX1-positive/insulin-negative ductal cells over
total ductal cells. For all in vivo studies at least 4 animals were used
KGF and Pancreatic Duct
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cells, we performed double immunofluorescent staining for Glut 2
and insulin on pancreatic sections of 4-day-old rats. Sections
adjacent to these double-stained sections were stained for CK20.
Cell culture
Human duct cell line Panc-1 used in this study was purchased
from ATCC (LCG Promochem Molsheim, France). Panc-1 cells
were grown in DMEM supplemented with 10% FBS and
penicillin–streptomycin (1%) in a humidified atmosphere of 95%
O2,5 %C O 2 at 37uC. The cells were regularly seeded into T75
flask (VWR International, Fontenay-sous-Bois, France). Media
were changed twice weekly.
Inhibition of MAP kinases ERK1/2 pathway
ERK1/2 pathway was inactivated by the inhibition of its
specific upstream activator MEK1. MEK1 inhibition was
performed both by using pharmacological inhibitor or by the
inhibition of its translation by the means of specific antisense
oligonucleotides.
Cells were seeded in twelve-well plates and after 6 h culture
with DMEM supplemented with 10% FBS, cells were changed to
serum-free medium for 3 days, followed by appropriate treatments
described below.
Pharmacological inhibition of MEK1 was achieved by the use of
specific inhibitor PD98059. Different doses (1, 10 and 20 mM) of
PD98059 were tested. For pharmacological inhibition of MEK1,
cells were pre-treated with the inhibitor 1 h before KGF
treatment. Twenty four hours after addition of KGF, cells were
processed for western blot analysis or for proliferation assay.
To inhibit MEK1 translation, MEK1 antisense morpholino-
oligonucleotides (Gene Tools LLC) (59-TGGGCGTCG-
GCTTCTTCTTGGGCAT-39) were designed based upon the
published rat and human common regions of MEK1 cDNA
sequence [GenBankTM accession number NM 002755 (human)
and NM 001008375 (rat)]. Antisense oligonucleotides were
delivered using the DMSO endoporter delivery system as
recommended by the manufacturer (Gene Tools LLC). Standard
non-specific morpholinos (59-CCTCTTACCTCAGTTA-
CAATTTATA-39) were used as control.
Cells were incubated with MEK1 antisense morpholino
oligonucleotides or with standard oligonucleotides (Std) for 24 h
and then supplemented with KGF (30 ng/ml) for another 24 h.
One hour before the end of the experiments, BrdU (10 mM) was
added to the culture media. Incubations were terminated by the
addition of lysis buffer for western blot analysis or by fixation in
4% formaldehyde for immunocytochemical analysis.
Western Blotting
Western blot analysis was performed to study phospho- and total-
ERK1/2, MEK1, cyclin D1 and cyclin D2 protein expression.
Briefly, 10 mg of protein were subjected to SDS-PAGE (10%
acrylamide gel) and then transferred to a PVDF membrane for 2 h
(120 V) using a Bio-Rad Mini Trans Blot electrophoretic transfer unit
(Bio-Rad, Marnes-la-Coquette, France). The membranes were
blocked for nonspecific binding with 5% nonfat dry milk in Tris-
buffered saline (TBS, 20 mM Tris-HCl, 150 mM NaCl, pH 7.4)
s u p p l e m e n t e dw i t h0 . 0 5 %T w e e n2 0( T T B S )a n dt h e np r o b e dw i t h
the specific primary antibodies. After 3 washes with TTBS,
membranes were incubated with appropriate horseradish peroxi-
dase-conjugated secondary antibodies. Separated proteins were
visualized by an ECL kit (GE Healthcare) and light emission was
captured on X-ray film (GE Healthcare). Intensities of the respective
bands were examined by densitometricanalysis (Scion Image Analyst
program).
Proliferation assay
Proliferation assay was performed with BrdU incorporation
method on Panc-1 cells using a Cell Proliferation Kit (GE
Healthcare). BrdU was added to the culture media 1 h before the
end of the experiments. Cells were fixed in 4% formaldehyde for
20 min then washed with PBS. Panc-1 cells were then stained for
BrdU according to manufacturer’s instructions. Cells were then
counterstained with hematoxylin.
Statistical analysis
Data are expressed as the mean values 6SEM. Comparisons
between the groups were performed by ANOVA and post-hoc
(Fisher) or Mann-Withney tests. p,0.05 was considered as
significant.
Figure 1. KGF stimulates cell proliferation and activates ERK1/2
pathway. (A) Panc-1 cells were cultured in serum-free medium with or
without KGF (30 ng/ml) or with 10% FBS for 24 h. BrdU was added to
the culture media 1 h before the end of the experiments. Results are
expressed as mean values 6SEM of three independent experiments. **
p,0.01. (B) Phosphorylation of ERK1/2 was evaluated by western blot
analysis in cell extracts from Panc-1 cells stimulated for 5, 20 and
60 minutes with KGF, or with 10% FBS for 20 minutes. Western blot
analysis of total-ERK1/2 protein was used as control.
doi:10.1371/journal.pone.0004734.g001
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I- in vitro studies
Stimulation of duct cell proliferation by KGF. Panc-1
cells have been rendered quiescent by 72 h serum deprivation
(control group) and were then treated with KGF or 10% FBS for
24 h. The exposure to KGF potently stimulated the mitotic
activity of the cells (Figure 1A) as evidence by the 200% increase of
the rate of cell proliferation in those cells as compared to that of
the control group. The stimulation of proliferation induced by
KGF was similar to that measured in cells treated with 10% FBS
(Figure 1A).
Activation of ERK1/2 pathway by KGF. The time-course
analysis of ERK1/2 phosphorylation in cells treated with KGF
showed a prompt activation of ERK1/2 which peaked at 5 min
after stimulation. The activation of ERK1/2 was transient and the
basal levels of ERK1/2 phosphorylation were recovered 1 h after
stimulation (Figure 1B).
At the time-point 20 min after stimulation, KGF-induced
activation of ERK1/2 resembled that induced by 10% FBS.
Inactivation of ERK1/2 pathway by MEK1 inhibitors and
its effects on KGF-induced cell proliferation. To establish
the functional link between ERK1/2 activation and the
stimulation of cell proliferation induced by KGF, we proceeded
to the inactivation of the only known upstream activator of
ERK1/2 proteins. MEK1 was first inactivated by its
pharmacological inhibitor PD98059. KGF-induced proliferation
of Panc-1 cells assessed by BrdU staining (Figure 2B) was
completely abolished by blockade of ERK1/2 phosphorylation
caused by PD98059 (Figures 2A and 2C). In contrast, MEK1
inactivation and the consequent inhibition of ERK1/2 pathway,
caused only a slight and non significant decrease in the rate of cell
proliferation induced by 10% FBS (Figure 2C).
Our results from experiments with pharmacological MEK1
inhibitor clearly designate MEK1-ERK1/2 pathway as the main
pathway involved in the transduction of KGF biological actions on
Figure 2. Inactivation of ERK1/2 pathway by pharmacological inhibitor abolishes KGF-induced Panc-1 cell proliferation. (A) Panc-1
cells were pre-incubated for 1 h with 20 mM, 10 mM and 1 mM of PD98059, an inhibitor of MEK1. Cells were then treated for 5 minutes with 30 ng/ml
KGF. Cell lysates were analyzed by western blot using specific antibodies against P-ERK1/2 and total-ERK1/2. (B) Panc-1 cells were cultured in serum-
free medium. Cells were then exposed or not to KGF or PD98059 alone, or to the combination of the two agents for 24 h. Cell proliferation was
assessed by BrdU staining (brown nuclei). Red arrows show BrdU-positive Panc-1 cells and blue arrows show BrdU-negative Panc-1 cells (actual
magnification6250). (C) Panc-1 cells were treated or not with 20 mM PD98059, 1 h prior to the 24 h incubation with KGF or 10% FBS. BrdU labelling
index of Panc-1 cells was evaluated and expressed as the percentage of BrdU-positive Panc-1 cells. Results are presented as mean values 6SEM of
three independent experiments. ** p,0.01.
doi:10.1371/journal.pone.0004734.g002
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nectedness of signaling networks, it cannot be ruled-out that
interactions with proteins beyond the one intended could be caused
by small kinase inhibitors [12,13]. To definitelyexclude the possibility
of non-specific effects of PD98059, we used a specific approach to
knock down MEK1 protein by antisense morpholino-oligonucleo-
tides. Morpholino-oligonucleotides are useful tools to silence gene
expression post-transcriptionally [14,15]. We first verified that
morpholino-oligonucleotides successfully penetrated into the cells
by the use of FITC-conjugated MEK1-AS (not shown). Then we
showed that the expression of MEK1 protein was decreased by about
40% in Panc-1 cells treated with MEK1-AS (Figure 3A).
Downregulation of MEK1 by specific antisense oligonucleotides
blunted ERK1/2 phosphorylation (Figures 3B). KGF-induced cell
proliferation was completely abolished in Panc-1 cells treated with
MEK1-AS (Figures 3C).
Induction of cell cycle regulators by KGF. We evaluated
the expression of D-type cyclins (D1 and D2) in Panc-1 cells by
western blot analysis. Cyclin D2 was not expressed in Panc-1 cells
(Figure 4A) whereas cyclin D1 was expressed at a low level in serum
deprived Panc-1 cells. We analyzed the effect of KGF on the
expression of cyclin D1, 8 h after incubation with the peptide. KGF
significantly increased the levels of cyclin D1 protein in the cells
(Figure 4B). Blockade of ERK1/2 pathway by PD98059 silenced
the KGF-induced expression of cyclin D1 indicating that induction
of this protein by KGF is ERK1/2 dependent (Figure 4B).
II- In vivo studies
Activation of ERK1/2 pathway by KGF. We first
investigated whether KGF induces ERK1/2 activation in the
pancreas of neonatal diabetic rats. We found a significant increase
of phosphorylated ERK1/2 in the whole pancreatic extracts of 2-
Figure 3. Inactivation of ERK1/2 pathway by antisense morpholino-oligonucleotides abolishes KGF-induced proliferation of Panc-1
cells. (A) Panc-1 cells were cultured in serum-free medium and treated for 24 h with MEK1 antisense morpholino-oligonucleotides (MEK1-AS,
10 nmol/ml) or standard morpholino-oligonucleotides (Std, 10 nmol/ml). Cell lysates were analyzed by western blot using specific antibody against
MEK1. Representative blots and MEK1 protein quantification are shown in Figure 3A. Results are expressed as mean values 6SEM of 4 independent
experiments. * p,0.05. (B) Panc-1 cells were treated with MEK1-AS or Std during 24 h, then stimulated with KGF for 5 minutes before the end of the
experiments. Cell lysates were analyzed by western blot for P-ERK1/2 and total-ERK1/2 expression. (C) Panc-1 cells were cultured in serum-free
medium and pre-treated with MEK1-AS during 24 h prior the addition of KGF or 10% FBS. BrdU labelling index of Panc-1 cells was evaluated and
expressed as the percentage of BrdU-positive Panc-1 cells. Results are presented as mean values 6SEM of three independent experiments. * p,0.05.
doi:10.1371/journal.pone.0004734.g003
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(Figure 5).
Inactivation of ERK1/2 pathway by MEK1 inhibitors and
its effects on KGF-induced duct cell proliferation. In order
to investigate the signaling pathways involved in the transduction
of the mitogenic effects of KGF on neonatal pancreatic duct cells
showed previously [6], we silenced MEK1 protein expression by
the use of anti-MEK1 morpholino-oligonucleotides, administrated
in vivo to the diabetic pups. During the treatments, all pups
tolerated standard morpholinos and MEK1-AS well. There were
no adverse effects involving general appearance, body weight, and
glycemia (data not show) and no pups died in relation with the
administrated treatment.
Western blot analysis of whole pancreatic extracts from 2-day-old
rats injected with MEK1-AS showed that the amount of MEK1
protein was significantly reduced (by 50%) in the pancreas,
confirming the efficiency of morpholino-oligonucleotides to inhibit
MEK1 translation in vivo (figure 6A). STZ/Std group exhibited no
difference in pancreas morphology compared to STZ/saline group.
Moreover duct cell proliferation assessed by BrdU incorporation
method in STZ/Std group was similar to that of STZ/saline group
(8.160.8% vs 7.660.3% respectively). Therefore for duct cell
proliferation and differentiation studies, STZ/Std group has been
taken as control for comparison with all other groups.
We showed that the inhibition of MEK1/ERK pathway
dramatically reduced the proliferation of ductal cells induced by
KGF in 2-day-old STZ rats as compared to STZ/Std group.
These data indicate that the KGF-stimulated proliferation of
neonatal duct cells is exclusively dependent on ERK1/2 activation
(Figure 6B). We also found a decrease in the rate of proliferation of
acinar cells (Figure 6B).
Activation of duct-to-beta cell differentiation by KGF. In
order to assess the mechanisms of ductal cell differentiation into
beta cells in STZ rats, we analyzed the ductal expression of PDX1
and Glut 2, as intermediate steps in the process of beta cell
neogenesis. We found that KGF significantly increased the
number of PDX1-positive/insulin-negative ductal cells in the
pancreas of 2-day-old pups (Figure 7). At the age of 4 days post
natal, a slight but not significant increase in the number of PDX1-
positive/insulin-negative ductal cells persisted in the KGF treated
rats (not shown). PDX1 regulates the expression of a number of
beta cell specific genes including Glut 2 [16,17]. We sought to
determine whether the early induction of PDX1 expression by
KGF is further followed by the activation of downstream effectors
involved in the acquisition of mature beta cell phenotype.
To address this point, we examined the expression of Glut 2, an
important effector for glucose sensing in terminally differentiated
beta cells, also reported as a marker of precursor cells with
potential to differentiate into beta cells [18]. At the age of 2 days
post natal (8 hours after KGF administration) the percentage of of
Glut 2-positive/insulin negative ductal cells was not greater in the
KGF treated group than that found in the age-matched untreated
STZ group (not shown). At the age of 4 days post natal, the
number of Glut 2-positive/insulin-negative ductal cells was
significantly increased in the pancreases of rats treated with
KGF compared to that found in the STZ control group (Figure 8).
Beta cell neogenesis can be indirectly estimated by the
evaluation of the number of single or small clusters of insulin
expressing cells within or in the vicinity of the epithelial wall of
pancreatic ducts. At the age of 4 (0.6160.17% of total ductal cells
in the STZ group vs 1.6260.07% of total ductal cells in the STZ/
KGF group) and 7 days post natal (1.0760.09% of total ductal
cells in the STZ group vs 2.2560.01% of total ductal cells in the
STZ/KGF group), the number of single beta cells or clusters of
beta cells budding from ducts was significantly higher (p,0.05) in
the KGF treated groups compared to the age-matched untreated
control groups.
Inactivation of ERK1/2 pathway and its impact on KGF-
induced expression of PDX1 in ductal cells. Rats treated
with MEK1-AS exhibited a slight but not significant decrease in
the number of PDX1-positive ductal cells in response to 8 h KGF
treatment as compared to STZ/Std rats treated with KGF
(Figure 7) suggesting that ERK1/2 activation is not required for
the expression of PDX1 in ductal cells.
Inactivation of PI3K/AKT pathway and its impact on
KGF-induced expression of PDX1 in ductal cells. The
implication of the PI3K/AKT pathway in the induction of PDX1
expression in exocrine cells had been reported in an adult model of
pancreatic regeneration [19]. In order to assess whether this
signaling pathway is involved in the transduction of KGF signal in
ductal cells in in the neonatal regenerating pancreas, we
Figure 4. Induction of D-type cyclins by KGF. Cell lysates were
analyzed by western blot for cyclin D1 and cyclin D2 expression. (A)
Cells were cultured in medium with 10% FBS. Basal levels of cyclin D2
were not detectable in Panc-1 cells as compared to its expression in
insulinoma cell line, INS-1 used as control for the specificity of antibody.
(B) Panc-1 cells were cultured in serum-free medium. Cells were then
exposed or not to KGF or PD98059 alone, or to the combination of the
two agents for 8 h. Cell lysates were analyzed by western blot for cyclin
D1 expression. Results are expressed as mean values 6SEM of three
independent experiments. * p,0.05.
doi:10.1371/journal.pone.0004734.g004
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of rats with the PI3K inhibitor abolished the effect of KGF on
PDX1 expression as evidenced by a significant decrease in the
number of PDX1 positive ductal cells in the pancreas of 2-day-old
KGF treated diabetic pups pre-treated with wortmannin,
compared to the KGF treated group, while this treatment did
not alter the basal number of PDX1 expressing ductal cells
(Figures 9A and 9B).
Inactivation of PI3K/AKT pathway and its impact on
KGF-induced ductal cell proliferation. We have also
evaluated the rate of ductal cell proliferation in the STZ/
wortmannin/KGF group, as compared to the STZ/KGF group.
This parameter was found to be similar in both groups (Figure 9C),
indicating that the PI3K/AKT pathway is implicated in the
differentiation but not in the proliferation process in the pancreatic
ductal cells. Interestingly, the proliferation of acinar cells was
dramatically reduced in the pancreas of wortmannin treated rats,
either alone or associated with the treatment with KGF (not
shown).
Discussion
Type 1 and type 2 diabetes are associated with absolute or
relative loss of pancreatic beta cells. The shortage of islet tissue
critically hampers the wide application of cell replacement therapy
for type 1 diabetes and unfortunately patients with type 2 diabetes
still suffer from the absence of curative treatments for the disease.
Alternative cellular sources with potential to be induced to express
beta cell phenotype can overcome beta cell deficiency and lead to
major advances for the cure of this devastating disease. Pancreatic
duct cells represent such an alternative source for generation of
new beta cells [1] either ex-vivo prior to transplantation, or in vivo
in the pancreas of diabetic patients.
During pancreas organogenesis, all pancreatic cell types arise
from common precursor cells residing in ductal structures which
result from evagination and branching of the ventral and dorsal
pancreatic buds [20–22]. Ducts are also important for the
generation of beta cells in the post natal life. This has been
illustrated during the compensatory attempt to replace the normal
beta cell population, for instance in animal models of cell injury
induced by subtotal pancreatectomy [23–25] or in neonatal
pancreas following beta cell destruction by the toxic agent
streptozotocin [9,26]. In these contexts apart from proliferation
of existing beta cells, differentiation of precursor cells located in
ductal epithelium participate to the recovery of the beta cell mass
[9,23,27–33]. A substantial body of evidence in the literature thus
designates pancreatic duct as an important source for generation
of new beta cells both in vitro and in vivo [1,25,34]. Therefore,
characterization of stimuli with potential to induce the expansion
of ductal cells and/or to drive their differentiation into beta cells is
of great importance.
We and others have previously showed that in vivo adminis-
tration of KGF induces ductal cell proliferation [5] and beta cell
regeneration in diabetic rats [6]. Modulation of signaling pathways
by external stimuli represents key strategy used by the cellular
machinery to regulate cell proliferation and differentiation
processes. The understanding of these mechanisms is essential
for the outcome of regenerative therapies of diabetes based on the
induction duct cell proliferation and differentiation. The present
study was undertaken to dissect the intracellular signaling
pathways which mediate the growth and differentiation promoting
effects of KGF in pancreatic ductal cells.
As a cell system to decipher the intracellular mechanisms
underlying the effects of KGF on ductal cell proliferation in vitro,
we used Panc-1 cells, a ductal cell line derived from human
adenocarcinoma. This cell line has been used in several studies as a
model for the induction of duct-to-beta cell differentiation [35,36].
As these cells have high proliferative capacity in the presence of
serum, all the experiments were conducted in the context of serum
starvation in order to induce quiescence. We showed that KGF
Figure 5. Activation of ERK1/2 pathway by KGF in the pancreas of neonatal diabetic rats. Two-day-old STZ diabetic rats were
administrated with 3 mg/kg KGF, 20 minutes before the sacrifice. Pancreases were removed and pancreatic protein extracts were analyzed by
western blot for the expression of P-ERK1/2 and total-ERK1/2 proteins. Four and five rats were analyzed in the STZ/saline and STZ/KGF group
respectively.
doi:10.1371/journal.pone.0004734.g005
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did 10% FBS. The induction of cell proliferation by KGF in
cultures of primary human ducts has been previously reported
[34,37]. However in these studies a thorough analysis of growth
promoting potential of KGF and the signaling pathways involved,
had not been made. The expression of specific KGF receptor
(FGFR2IIIb) having been described in this cell line [38,39], we
sought to investigate the post-receptor signaling molecules which
mediate the effects of KGF on cell proliferation. One of the most
common signaling pathways linked to cell response to growth
factors is the mitogen-activated protein kinases (MAPK) pathway.
Among the three main MAPK cascades (ERK1/2, JNK and P38),
ERK1/2 are predominantly activated by growth factors whereas
P38 and JNK transduce stress-related stimuli such as heat shock
and inflammatory cytokines [40,41]. We analyzed the implication
of ERK1/2 pathway in the mediation of KGF proliferative effects
on ductal cells. The only known upstream activators of ERK1/2
are MEK proteins. We first inactivated MEK1 by its pharmaco-
logical inhibitor PD98059. We further confirmed the specificity of
MEK inactivation by the use of antisense morpholino-oligonucle-
otides (MEK1-AS) specifically designed to inhibit MEK1 transla-
tion. Strikingly, in both cases blockade of ERK1/2 phosphoryla-
Figure 6. Inactivation of ERK1/2 pathway by MEK1-AS abolishes KGF-induced duct cell proliferation. (A) Rats from STZ/Std and STZ/
MEK1-AS groups were sacrificed at day 2 post natal. Pancreases were removed and pancreatic protein extracts were analyzed by western blot using a
specific MEK1 antibody. Representative blots and MEK1 protein quantification are shown in Figure 6A. Results are expressed as mean values 6SEM.
Four rats were analyzed in each experimental group. * p,0.05. (B) BrdU (brown nuclei) and CK20 staining (red cytosol) of pancreatic sections from 2-
day-old STZ/Std/KGF and STZ/MEK1-AS/KGF newborns (actual magnification 6500). (C) Ductal cell proliferation was assessed by BrdU staining of
pancreatic sections of STZ/Std, STZ/MEK1-AS, STZ/Std/KGF and STZ/MEK1-AS/KGF groups. BrdU labelling index of ductal cells in all experimental
groups was evaluated in 2-day-old pups and the results were expressed as the percentage of BrdU-positive ductal cells. Three to five rats were
analyzed in each experimental group. ** p,0.01.
doi:10.1371/journal.pone.0004734.g006
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induced by KGF. From these data we clearly established that
ERK1/2 activation is necessary and sufficient for the mediation of
growth promoting effects of KGF in pancreatic ductal cells in
vitro. The mediation of mitogenic effects of KGF by ERK1/2
signaling has also been reported in other cell types such as
endometrial cells [42,43] while other effects of KGF such as
regulation of cell migration were mediated by MAP Kinase P38
[43]. The cell cycle is regulated at various checkpoints, of which
the G1–S phase represents the most important step. At this
checkpoint, extra-and intracellular signals are integrated and
transmitted into cells to determine whether they enter the cell
division phase, apoptosis or the quiescence G0 phase [44]. Cyclins
are major regulators of cell cycle transition and by their binding to
cyclin-depedent kinases they act as molecular switches for the G0/
G1-S phase transition in many cell types. We first established that
cyclin D1 was expressed in Panc-1 cells while cyclin D2 was not
detectable in this cell type. KGF treatment of Panc-1 cells
significantly increased the levels of cyclin D1 protein and the
blockade of the ERK signaling by PD98059 prevented the
induction of cyclin D1 expression by KGF. Kornmann et al. have
previously showed that cyclin D1 is over-expressed in ductal
cancer cells and treatment of cells with cyclin D1 antisense was
associated with significant inhibition of in vitro duct cell
proliferation [45]. However the induction of cyclin D1 by KGF
in pancreatic ductal cells has to date not been addressed. Thus,
our report in support of previous studies [45,46] suggests that
cyclin D1 may represent a final common effector for mitogenic
signaling via KGF receptor.
Although previous in vitro studies have partly identified the
signaling pathways of growth factor-mediated proliferation in
pancreatic ductal cells in vitro [37,47], the intracellular mecha-
nisms of KGF-induced duct cell proliferation in vivo are still
poorly understood. Therefore, in this study we explored how the
pathways induced by KGF in vitro, translate into their in vivo
activation. In a previous work we have reported that in vivo
administration of KGF to neonatal diabetic rats stimulated beta
cell regeneration via the induction of duct cell proliferation and
their subsequent differentiation into insulin producing cells [6].
Here we confirmed the in vivo growth promoting effect of ductal
cells by KGF in the pancreas of STZ diabetic rats. To determine
the relevance of our in vitro findings to the in vivo situation we
assessed the implication of ERK1/2 pathway in the KGF-induced
duct cell proliferation. We used a specific approach based on the
administration of anti-MEK1 antisense oligonucleotides to the
pups. We demonstrated for the first time that MEK1 can be
successfully knocked down in the pancreas by the use of antisense-
oligonucleotides in vivo. This approach, more specific than
pharmacological inhibition and less harmful than adenovirus
mediated gene inactivation was well tolerated by the pups and no
general deleterious effects due to the downregulation MEK1 in
other organs during the time course of our study were observed
(not shown). This is the first demonstration of the in vivo use of
morpholino-oligonucleotides as a safe and specific post-transcrip-
tional gene silencing approach in newborn rats. The blockade of
ERK1/2 in vivo totally abolished the KGF-induced proliferation
of ductal cells indicating that, at least in the neonatal pancreas,
ERK1/2 pathway is the exclusive signaling pathway responsible
for duct cell proliferation induced by KGF. The mediation of
growth promoting effects of KGF by ERK1/2 signaling has also
been reported in culture of embryonic pancreatic rudiments [47].
ERK1/2 activation has been shown to occur in a model of adult
pancreas regeneration after pancreatectomy [48]. Immunohisto-
chemical analysis revealed that in this model, ERK phosphory-
lation can be seen only in duct cells and not in acinar cells during
pancreatic regeneration [49,50]. Ductal compartment of the
pancreas is admitted to harbour precursor cells for islet neogenesis.
Therefore, the activation of ERK proteins in the duct in
regenerating pancreas may play an indirect role in endocrine cell
neogenesis by increasing the number of so-called progenitor cells.
Here we have further explored the possibility that, beyond the
stimulation of cell proliferation in the ductal compartment, other
steps of beta cell neogenesis from ducts could be directly
modulated by KGF. In order to address this question, we
examined the expression of beta cell specific markers in ductal
cells in the pancreas of neonatal diabetic rats. The homeodomain
Figure 7. Activation of duct- to- beta cell differentiation by
KGF. PDX1-positive/insulin-negative ductal cells were quantified after
insulin/PDX1 double staining of pancreatic sections of the 2-day-old
STZ/Std, STZ/Std/KGF and STZ/MEK1-AS/KGF rats. Results are expressed
as the percentage of PDX1-positive/insulin-negative ductal cells over
total ductal cells. Four rats were analyzed in each experimental group. *
p,0.05.
doi:10.1371/journal.pone.0004734.g007
Figure 8. Activation of duct- to- beta cell differentiation by
KGF. Glut 2-positive/insulin-negative cells were quantified after insulin/
Glut 2 double staining of pancreatic sections of the 4-day-old STZ/saline
and STZ/KGF groups. Results are expressed as the percentage of Glut 2-
positive/insulin-negative ductal cells over total ductal cells. Four rats
were analyzed in each experimental group. * p,0.05.
doi:10.1371/journal.pone.0004734.g008
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morphogenesis during development [20,51,52] and a transcrip-
tional regulator of insulin synthesis and secretion in mature beta
cells [53–55]. It has been strongly suggested that during the
postnatal life, PDX1 may also be essential for neogenesis of
endocrine cells by differentiation from precursor cells that reside
among the cells lining the pancreatic ducts [56–58]. The
examination of pancreatic sections revealed that the number of
PDX1-positive/insulin-negative cells was significantly higher
among ductal cells of KGF treated STZ rats. PDX1-positive/
insulin-negative cells can be considered as cells committed toward
a beta cell-like phenotype without having achieved terminal
differentiation yet. This novel finding designates for the first time
KGF as a differentiation inducing agent through the stimulation of
PDX1 expression in ductal cells. In a study in primary islets and in
INS1 beta cells, ERK1/2 activation has been shown to be
required for the regulation of important transcription factors such
as Beta2, PDX-1, and E12/47 [59]. Therefore we assessed the
implication of ERK1/2 pathway in the induction of PDX1
expression in ductal cells induced by KGF. We found that the
Figure 9. Inactivation of PI3K/AKT pathway by wortmannin abolishes KGF-induced duct-to-beta cell differentiation but does not
alter the effect of KGF on proliferation. (A) Double staining for insulin (red cytosol) and PDX1 (brown nuclei) were performed on pancreatic
sections of STZ, STZ/KGF, STZ/wortmannin and STZ/wortmannin/KGF rats (wortmannin was administrated at the dose of 0.75 mg/kg body weight).
Differentiated beta cells express both insulin and PDX1 (blue arrow). A subset of ductal cells express PDX1 (red arrow) while the majority of ductal
cells are PDX1 negative (green arrow) (actual magnification 6500). d=duct. (B) PDX1-positive / insulin-negative ductal cells were quantified after
insulin/PDX1 staining on pancreatic sections of the 2-day-old STZ, STZ/KGF, STZ/wortmannin and STZ/wortmannin/KGF rats. Results are expressed as
the percentage of PDX1-positive/insulin-negative cells over total ductal cells. Four rats were analyzed in each experimental group. * p,0.05; **
p,0.01. (C) Ductal cell proliferation was assessed by BrdU staining of pancreatic sections of the 2-day-old STZ, STZ/KGF, STZ/wortmannin and STZ/
wortmannin/KGF rats and the results were expressed as the percentage of BrdU-positive ductal cells. Four rats were analyzed in each experimental
group. * p,0.05; ** p,0.01.
doi:10.1371/journal.pone.0004734.g009
KGF and Pancreatic Duct
PLoS ONE | www.plosone.org 10 March 2009 | Volume 4 | Issue 3 | e4734blockade of this pathway by the administration of anti-MEK1
antisense-oligonucleotides did not affect the KGF-induced expres-
sion of PDX1 in ducts, suggesting that the induction of PDX1 in
those cells in not dependent upon ERK1/2 activation. Several
papers by Evers group have reported that in the context of
pancreas regeneration after pancreatectomy in adult rodents, the
induction of PDX1 expression in duct cells is regulated by the
PI3K pathway [49,50]. However whether KGF acts through this
pathway to induce PDX1 expression in ductal cells had not been
reported. We addressed this question in the present study and
showed that the effect of KGF on the ductal expression of PDX1 is
totally abolished in animals treated with wortmannin, providing
evidence on the role of the PI3K/AKT pathway in the mediation
of the KGF signal for PDX1 expression in ducts. As an additional
hallmark of the progression of duct-to-beta cell differentiation
process, we investigated the expression of Glut 2 in ductal cells.
Glut 2, a transcriptional target of PDX1, is an essential effector of
the glucose sensing machinery in terminally differentiated beta
cells. However, Glut 2 has also been reported as a marker of
precursor cells during the early stages of pancreas development
[60] and in a subset of precursor cells during beta cell regeneration
in experimental models of diabetes [18]. Our histological
examination of the pancreatic sections revealed that the number
of Glut 2-positive/insulin-negative cells among the ductal
compartment is significantly increased in rats treated with KGF,
suggesting that this growth factor induces duct-to-beta cell
differentiation by the sequential activation of beta cell specific
markers in ductal cells. Whether the expression of Glut 2 in ductal
cells is induced by KGF directly or by transactivation effect of
PDX1 is not clear but the fact that at an earlier stage (day 2 post
natal) the number of Glut 2-positive ductal cells was not greater
than that found in the age-matched untreated control group,
suggests that the increased number of Glut 2-positive ductal cells
observed at day 4 post natal might be due to the induction of Glut
2 by PDX1.
Although PDX1 and Glut 2 are required for the initiation of the
process of beta cell differentiation, the expression of many other
factors including transcription factors are necessary for the full
differentiation of beta cells [61]. However, only the presence of
insulin can testify that the process of beta cell neogenesis has
reached full completion. Therefore we evaluated the number of
single or small clusters of insulin containing cells within or in the
vicinity of the ductal epithelium.
The previous [6] and the present observation that the number
of duct-associated insulin-positive cells was greater in KGF treated
rats at the age of 4 and 7 days post natal compared to the age-
matched untreated rats suggests that ductal cells expressing PDX1
and Glut 2 eventually differentiate into mature insulin producing
beta cells.
To the best of our knowledge, our study is the first in providing
evidence of a direct differentiation promoting effect of KGF on
ductal cells and for the identification of the signaling pathways
involved in this process. We demonstrated that in vivo, in the
context of beta cell deficiency, exogenous KGF acts on pancreatic
ductal cells through two distinct mechanisms: 1) via the induction
of their proliferation through an ERK1/2 dependent mechanism.
The activation of cell proliferation in ductal compartment which
includes that of progenitor cells would increase the number of the
latter and indirectly promote the process of beta cell neogenesis. 2)
via the induction of PDX1 expression through a PI3K dependent
mechanism in a subpopulation of ductal cells, committing those
cells towards differentiation into beta cell. Different duct cell
subpopulations may differ in their precursor capacity. We have
demonstrated that KGF acts in a unique cell type, via distinct
signaling pathways to trigger the commitment of different subsets
of ductal cells towards a beta cell-like phenotype. The transition
from duct to beta cell phenotype requires a complex network of
signaling pathways whose activation / inactivation in a finely
coordinated manner ensures the proper differentiation process to
take place [35]. The identification of agents with the potential to
trigger this transition is of great interest. Our present work
designates KGF as an effective agent for the in vivo induction of
duct-to-beta cell differentiation and might have have important
implications for the regenerative therapies of diabetes.
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